



## Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

October 21, 2025

PASADENA, Calif.--(BUSINESS WIRE)--Oct. 21, 2025-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that a global licensing and collaboration agreement with Novartis, previously announced on September 2, 2025, has now closed. Closing of the transaction was subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 and other customary conditions.

### Summary of License and Collaboration Agreement

Novartis received an exclusive worldwide license to research, develop, manufacture, and commercialize ARO-SNCA, a preclinical stage program that utilizes Arrowhead's Targeted RNAi Molecule (TRiM™) platform for subcutaneous administration and delivery to the CNS designed to target the gene that encodes the alpha-synuclein protein as a potential treatment for patients with Parkinson's Disease, and other synucleinopathies. Novartis may also select additional collaboration targets outside of Arrowhead's current pipeline to be developed using the TRiM™ platform.

For all licensed programs under the agreement, Arrowhead will conduct and complete preclinical research activities necessary to enable a clinical trial application (CTA) filing. Novartis will then assume sole control over development, manufacturing, medical affairs, and commercialization activities.

### Summary Financial Terms

Arrowhead will receive a \$200 million upfront payment from Novartis and is also eligible to receive development, regulatory, and sales milestone payments of up to \$2 billion. Arrowhead is further eligible to receive tiered royalties on commercial sales up to the low double digits.

### About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead's RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit [www.arrowheadpharma.com](http://www.arrowheadpharma.com), or follow us on X (formerly Twitter) at [@ArrowheadPharma](https://twitter.com/ArrowheadPharma), [LinkedIn](https://www.linkedin.com/company/arrowhead-pharmaceuticals), [Facebook](https://www.facebook.com/arrowheadpharma), and [Instagram](https://www.instagram.com/arrowheadpharma). To be added to the Company's email list and receive news directly, please visit <http://ir.arrowheadpharma.com/email-alerts>.

### Safe Harbor Statement under the Private Securities Litigation Reform Act:

*This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "hope," "intend," "plan," "project," "could," "estimate," "continue," "target," "forecast" or "continue" or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.*

**Source:** Arrowhead Pharmaceuticals, Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20251021267147/en/): <https://www.businesswire.com/news/home/20251021267147/en/>

Arrowhead Pharmaceuticals, Inc.  
Vince Anzalone, CFA  
626-304-3400  
[ir@arrowheadpharma.com](mailto:ir@arrowheadpharma.com)

**Investors:**  
LifeSci Advisors, LLC  
Brian Ritchie  
212-915-2578

[britchie@lifesciadvisors.com](mailto:britchie@lifesciadvisors.com)

**Media:**

LifeSci Communications, LLC

Kendy Guarinoni, Ph.D.

724-910-9389

[kquarinoni@lifescicomms.com](mailto:kquarinoni@lifescicomms.com)

Source: Arrowhead Pharmaceuticals, Inc.